Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment : results of the MOPEAD Study in Spain
Ortiz-Zúñiga, Ángel Michael (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Rodriguez-Gómez, Octavio (Institut Català de Neurociènces Aplicades)
Hernández, Cristina (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Rodrigo, Adrian (GMV Soluciones Globales Internet SAU. Valencia)
Jamilis, Laura (GMV Soluciones Globales Internet SAU. Valencia)
Campo, Laura (International Corporate Affairs, Alzheimer's Disease, Eli Lilly and Co. Italy)
Alegret, Montserrat (Universitat Internacional de Catalunya. Institut Català de Neurociènces Aplicades)
Boada, Mercè (Institut Català de Neurociènces Aplicades)
Ciudin, Andreea (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Simó Canonge, Rafael (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	Introduction: Although the Diabetes Specific Dementia Risk Score (DSDRS) was proposed for predicting risk of dementia at 10 years, its usefulness as a screening tool is unknown. For this purpose, the European consortium MOPEAD included the DSDRS within the specific strategy for screening of cognitive impairment in type 2 diabetes (T2D) patients attended in a third-level hospital. Material and Methods: T2D patients > 65 years, without known cognitive impairment, attended in a third-level hospital, were evaluated. As per MOPEAD protocol, patients with MMSE ≤ 27 or DSDRS ≥ 7 were referred to the memory clinic for complete neuropsychological assessment. Results: 112 T2D patients were recruited. A total of 82 fulfilled the criteria for referral to the memory unit (43 of them declined referral: 48. 8% for associated comorbidities, 37. 2% lack of interest, 13. 95% lack of social support). At the Fundació ACE's Memory Clinic, 34 cases (87. 2%) of mild cognitive impairment (MCI) and 3 cases (7. 7%) of dementia were diagnosed. The predictive value of DSDRS ≥ 7 as a screening tool of cognitive impairment was AUROC = 0. 739, p 0. 024, CI 95% (0. 609-0. 825). Conclusions: We found a high prevalence of unknown cognitive impairment in TD2 patients who attended a third-level hospital. The DSDRS was found to be a useful screening tool. The presence of associated comorbidities was the main factor of declining referral.
Nota:	Altres ajuts: This research was funded by the European Innovative Medicines Initiative (IMI2) Project-grant number 115985.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Type 2 diabetes ; Mild cognitive impairment ; Alzheimer's disease
Publicat a:	Journal of clinical medicine, Vol. 9 Núm. 9 (2020) , p. 2726, ISSN 2077-0383

DOI: 10.3390/jcm9092726
PMID: 32847012

10 p, 661.4 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats